Abstract Details

Title Gliomatosis cerebri: Management and survival in the United States

Topic Neuro-oncology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-005

Objective We describe the management of gliomatosis cerebri (GC) and provide clinical basis of aggressive behavior in gliomas.

Background Gliomatosis cerebri (GC) is an extensive growth pattern involving three contiguous lobes.

Design/Methods We analyzed the National Cancer Database (NCDB) from 2004-2014. We compared clinical and survival patterns of GC to histologically confirmed grade III diffuse gliomas (high-grade gliomas, HGG).

Results 397 GC cases were identified and compared to 18,647 HGG. The median age of GC patients was 63 years, significantly older compared to HGG (50 years, p<0.01). Twenty-three (5.8%) patients were younger than 19 years in the GC group, compared to 6.3% in the HGG group. Patients were more commonly white 86.9%-88.9%, with 5.8%-6.8% Hispanics, and 6.3%-5.9% blacks in the GC and HGG group. In the GC group, around 30% of patients were diagnosed by imaging/clinical criteria. Over 25% of the GC cases were graded as WHO grade III, 15.4% as grade II, and 4% as grade IV. The preferred treatment modality for GC was watchful waiting (35.3%), followed by radiation and chemotherapy (17.9%), and radiation, chemotherapy and surgery (14.9%). Treatment was more aggressive in HGG, with only 6.5% without treatment. Surgical resection was performed in 28.5% of GC patients, compared to 67.9% of HGG. Chemotherapy only offered the best 5-year survival advantages for GC patients. Median survival in GC was 11.9 months; significantly shorter than 32.7 months of HGG (p<0.0001). Grade IV was the only significant risk factor for mortality for GC patients.

Conclusions

Survival was significantly lower in GC compared to other HGG. Treatment for GC is based on radiation and chemotherapy. Over 35% of GC patients did not receive any form of treatment, which was significantly higher compared to HGG, and remains an undertreated disease. Further understanding of the biological aspects associated with this growth pattern is warranted.

Authors/Disclosures
Catherine Garcia, MD (MD Anderson Cancer Center) PRESENTER	Dr. Garcia has nothing to disclose.
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��